Healthcare Industry News: PHER-O2
News Release - January 30, 2008
Sanguine Corporation Opens Satellite Office in West Chester Pennsylvania
PASADENA, Calif.--(HSMN NewsFeed)--Sanguine Corporation (OTC Bulletin Board: SGNC ) is pleased to announce that it will be opening an office in West Chester, Pennsylvania, to expand its operations and to secure east coast representation. The West Chester office will house Sanguine’s newly formed life sciences division. The focus of the life sciences division is to advance SGNC through the development and acquisition of projects and technologies that will produce revenue for the Company. The West Chester office will also be increasing the current efforts to commercialize Sanguine’s flagship product, PHER-02.West Chester is located just outside of Philadelphia, Pennsylvania, an hour from Baltimore Maryland and an hour and a half from New York City and Washington D.C. This ideal location is going to give Sanguine much easier access to some of the largest cities, hospitals and universities in the country.
David Nelson, Sanguine’s CFO, said, “The opening of this new office is an integral component in our strategy to advance Sanguine. We anticipate many good things coming from this satellite office.”
About Sanguine
Sanguine Corporation, a development stage bio-pharmaceutical company, focuses on the development of an oxygen-carrying synthetic substitute for human red blood cells and various other areas requiring oxygen profusion. The company is developing a synthetic red blood cell product, PHER-O2 that consists of perfluoro-decalin molecules or synthetic red blood cells, purified water, and a synthetic and fluorinated surfactant to hold the emulsion together. PHER-O2 is under Phase II clinical trials and has oxygen-carrying capacity.
For information related to the Sanguine Corporation, contact Investor Relations: Michael Dancy, 801-746-3570, email: medancy@allwest.net, or visit: www.sanguine-corp.com.
Forward-looking statements in this release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company’s products, increased levels of competition for the Company, new products and technological changes, the Company’s dependence on third-party suppliers, and other risks detailed from time to time in the Company’s periodic reports filed with the Securities and Exchange Commission.
Source: Sanguine
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!